Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Cevimeline hydrochloride
Drug ID BADD_D00425
Description Cevimeline is a parasympathomimetic agent that act as an agonist at the muscarinic acetylcholine receptors M1 and M3. It is indicated by the Food and Drug Administration for the treatment of dry mouth associated with Sjögren's syndrome.
Indications and Usage For the treatment of symptoms of dry mouth in patients with Sjögren's Syndrome.
Marketing Status approved
ATC Code N07AX03
DrugBank ID DB00185
KEGG ID D00661
MeSH ID C059240
PubChem ID 123603
TTD Drug ID D0Q4CS
NDC Product Code 59651-422; 66406-0269; 0054-0334; 0713-0883; 40032-999; 46014-1002; 58159-087; 63395-201; 72888-118; 0713-0937; 42973-228; 72166-012; 43386-999; 16571-657
UNII P81Q6V85NP
Synonyms cevimeline | 2-methyspiro(1,3-oxathiolane-5,3)quinuclidine | AF 102B, (trans)-isomer | AF-102B | AF 102B | AF102B | Evoxac | FKS 508 | FKS-508 | SNI 2011 | SNI-2011 | AF 102B, (cis-(+))-isomer | cevimeline hydrochloride
Chemical Information
Molecular Formula C10H18ClNOS
CAS Registry Number 107220-28-0
SMILES CC1OC2(CN3CCC2CC3)CS1.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Pyuria20.08.02.016; 11.01.08.043--Not Available
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rectal haemorrhage24.07.02.018; 07.12.03.001--
Renal pain20.02.03.003--Not Available
Respiratory disorder22.02.07.002--Not Available
Retinal deposits06.09.03.005--Not Available
Retinal disorder06.08.03.005--Not Available
Rheumatoid arthritis15.01.03.001; 10.04.06.001--Not Available
Rhinitis22.07.03.006; 11.01.13.004--
Rosacea23.02.08.001--Not Available
Salivary gland enlargement07.06.03.002--Not Available
Salivary gland pain07.06.02.002--Not Available
Salivary hypersecretion07.06.01.009--Not Available
Scleritis10.02.01.025; 06.04.07.002--Not Available
Scleroderma15.06.01.002; 23.03.02.005; 10.04.07.001--Not Available
Seborrhoea23.02.07.001--Not Available
Seizure17.12.03.001--
Sepsis11.01.11.003--
Sexual dysfunction21.03.02.003; 19.08.05.002--Not Available
Sialoadenitis11.01.04.002; 07.06.04.002--
Sinusitis22.07.03.007; 11.01.13.005--
Skin discolouration23.03.03.005--Not Available
Skin disorder23.03.03.007--Not Available
Skin exfoliation23.03.07.003--Not Available
Skin hypertrophy23.01.04.002--Not Available
Skin papilloma16.26.01.002; 11.05.07.001; 23.10.01.002--
Skin ulcer24.04.03.007; 23.07.03.003--
Smear cervix abnormal13.20.02.001--Not Available
Somnolence19.02.05.003; 17.02.04.006--
The 10th Page    First    Pre   10 11 12 13    Next   Last    Total 13 Pages